Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4728851 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11USP2SMN1; SMN2HDAC2 | |
| SCHEMBL5743508 | 0.91 | CYP4F2 (0.48) | CYP4F2CYP4A11USP2SMN1; SMN2PKM | |
| SCHEMBL4781731 | 0.88 | CYP4F2 (0.52) | CYP4F2CYP4A11USP2SMN1; SMN2PKM | |
| SCHEMBL4919558 | 0.87 | CYP4F2 (0.56) | CYP4F2CYP4A11USP2SMN1; SMN2HDAC2 | |
| SCHEMBL4919554 | 0.87 | CYP4F2 (0.56) | CYP4F2CYP4A11USP2SMN1; SMN2HDAC2 | |
| SCHEMBL16095520 | 0.83 | MMP2 (0.42) | CYP4F2CYP4A11USP2SMN1; SMN2PKM | |
| SCHEMBL390461 | 0.83 | USP2 (0.42) | CYP4F2CYP4A11USP2SMN1; SMN2PKM | |
| SCHEMBL1958618 | 0.82 | PKM (0.48) | CYP4F2CYP4A11USP2SMN1; SMN2PKM | |
| SCHEMBL23527934 | 0.82 | USP2 (0.46) | CYP4F2CYP4A11USP2SMN1; SMN2PKM | |
| SCHEMBL14155541 | 0.82 | USP2 (0.46) | CYP4F2CYP4A11USP2SMN1; SMN2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008012635-A2 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051419-A1 | AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, CCND2, CCND1 | CYP4F2 2966/4885CYP4A11 3825/4885USP2 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.